{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073321","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.473695+00:00","generated_at":"2026-05-17T16:48:12.220791+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incannex reports positive Phase 2 data for IHL-42X in obstructive sleep apnoea; AHI reductions up to 83%","bullets":["Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.","41.2% of high-dose group achieved >30% AHI reduction; 14.7% had >50% reduction; no reduction in REM sleep.","89.5% of patients reporting improvement described change as meaningful; benefits included improved sleep quality and reduced daytime fatigue.","No serious adverse events; treatment-emergent adverse effects infrequent, mild/moderate; drug well tolerated.","CEO notes share price volatility, states company is well-capitalized and considering strategic levers including anti-dilution measures."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073321","json":"https://secwatch.observer/filing/0001213900-25-073321.json","markdown":"https://secwatch.observer/filing/0001213900-25-073321.md","text":"https://secwatch.observer/filing/0001213900-25-073321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/0001213900-25-073321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/ea0252400-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:48:12.220791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}